Core Viewpoint - The report outlines the continuous supervision and guidance provided by Guotai Junan Securities for Huahai Qingke Co., Ltd. during the first half of 2025, emphasizing the company's compliance with regulations and its operational performance [2][9]. Summary by Sections Continuous Supervision Work - The sponsor has established a continuous supervision system to ensure the company adheres to regulatory obligations, including information disclosure and operational compliance [2][3]. - The sponsor has assisted the company in developing internal systems and decision-making processes to meet legal and regulatory requirements [3][4]. - The company has maintained transparency in its information disclosure, ensuring it is accurate, complete, and timely [3][4]. Financial Performance - For the first half of 2025, the company reported a revenue of approximately RMB 1.95 billion, a year-on-year increase of 30.28% [17]. - The total profit reached approximately RMB 549.78 million, reflecting an 11.66% increase compared to the previous year [17]. - The net profit attributable to shareholders was approximately RMB 505 million, marking a 16.82% increase [17]. R&D and Innovation - The company has a strong focus on R&D, with R&D expenses accounting for 12.63% of revenue, an increase from 11.72% in the previous year [17][22]. - The company has developed a robust R&D team of 722 members, representing 31.99% of its total workforce [19][20]. - The company has obtained 500 patents and 39 software copyrights, showcasing its commitment to innovation [19][20]. Risk Management - The company faces risks related to core competitiveness, including potential talent loss and technological advancements in the semiconductor equipment industry [9][10]. - The company has established a quality management system to ensure product quality and customer satisfaction [20][21]. - The company is exposed to financial risks, particularly concerning accounts receivable and customer concentration [12][13]. Use of Raised Funds - The company raised a total of RMB 364.43 million through its IPO, with a net amount of RMB 348.99 million after deducting issuance costs [2][23]. - As of June 30, 2025, the company has utilized RMB 111.58 million of the raised funds for designated projects [23]. - The company has ensured compliance with regulations regarding the management and use of raised funds [23].

Core Insights - The company, Huahai Qingshi (688120), reported a revenue of 1.95 billion yuan for the first half of 2025, representing a year-on-year growth of 30.28% [1] - The net profit attributable to shareholders reached 505 million yuan, an increase of 16.82% year-on-year, while the net profit excluding non-recurring items was 460 million yuan, up 25.02% [1] - The basic earnings per share stood at 2.14 yuan [1] Business Performance - The company's core product matrix showed strong performance, particularly in CMP equipment, which has seen significant technological advancements and market expansion [2] - The new CMP polishing system, Universal-H300, has received bulk repeat orders and achieved large-scale shipments [2] - Advanced process CMP equipment orders have increased significantly, with successful process validation at several leading domestic clients [2] Product Development - The company has developed thinning equipment suitable for advanced packaging and front-end wafer manufacturing, achieving substantial results during the reporting period [2] - The 12-inch ultra-precision wafer thinning machine, Versatile-GP300, saw a significant increase in order volume due to its excellent performance [2] - The 12-inch wafer thinning and film application integrated machine, Versatile-GM300, has been successfully adopted by major domestic semiconductor companies [2] Ion Implantation Equipment - The company’s subsidiary, Xinyu, successfully delivered its first 12-inch low-temperature ion implanter, iPUMA-LT, to a leading domestic logic chip manufacturer [3] - The company is expanding its product matrix to include medium and high-energy ion implanters to meet diverse manufacturing needs [3] Platform Strategy and R&D Investment - The "equipment + service" platform strategy is showing results, with an increase in the scale of key consumables and maintenance services as CMP equipment market share grows [3] - The company’s wafer regeneration business has received bulk orders from major production lines, with a project in Kunshan aiming for a monthly capacity of 200,000 wafers [3] - R&D investment reached 246 million yuan in the first half of 2025, a year-on-year increase of 40.44%, with R&D expenses accounting for 12.63% of revenue [3]